Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 studyNizar M. Tannir, Michael E. Hurwitz, Giovanni Grignani et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 27
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)Nizar M. Tannir, Oleg Karyakin, Maria Nirvana Formiga et al.|Journal of Clinical Oncology|2024Cited by 26
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02Arlene O. Siefker‐Radtke, Nizar M. Tannir, Daniel C. Cho et al.|European Urology|2022Cited by 20